SeeThruEquity Issues Company Note on Cynapsus Therapeutics
Thursday, 09 October 2014 09:00 AM
New York, NY / ACCESSWIRE / October 9, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on Cynapsus Therapeutics (TSX: CTH.V; OTCQX: CYNAF), a specialty pharmaceutical company developing an oral (sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for "off" motor symptoms of Parkinson's disease.
"We believe the Civitas acquisition sets a compelling valuation data point in the Parkinson's disease space. With a market cap of C$53.7mn, Cynapsus is trading at roughly 1/10th the purchase price of Civitas. The company expects to initiate a Phase III trial in early 2015 and have pivotal Phase III data on APL-130277 by the end of 2015 or in early 2016," stated Ajay Tandon, CEO of SeeThruEquity.
Civitas Therapeutics acquisition provides valuation data point
On September 24, 2014, Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that it had entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525mn in cash. Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinson's disease (PD). The acquisition also includes rights to Civitas' proprietary ARCUS(tm) pulmonary delivery technology and manufacturing facility with commercial-scale capabilities based in Chelsea, MA. CVT-301 is a system comprised of a dry powder L-dopa formulation that is contained within blister-packed capsules and administered via a proprietary, pocket-size, reusable inhaler. CVT-301 can provide rapid delivery of L-dopa in conjunction with a patient's optimized oral L-dopa regimen. The pivotal Phase 3 study for treatment of OFF episodes in people with PD is expected to begin enrolling in early 2015 and if successful, a filing for regulatory approval in the United States is expected by the end of 2016. The Michael J Fox Foundation (MJFF) provided grants totaling $1.3mn in the development of CVT-301, and Civitas is the fourth MJFF-funded program to be acquired, partner with a major pharmaceutical firm or file for an initial public offering in the past month. Acorda forecasts peak US sales of CVT-301 of $500mn. Acorda stock jumped on the news, rising 28.2% on September 24th to $37.62 per share. As of October 3rd, shares closed at $34.18.
APL-130277 will soon be in the spotlight
We are very positive on the Civitas transaction as we feel that it highlights numerous investment points that make us positive on shares of Cynapsus. APL-130277 represents a potentially attractive competitive alternative product to CVT-301, as it is a thin film sheet that dissolves in the mouth within a few minutes to provide convenient, rapid and pain-free relief. Cynapsus, which has also received grants from MJFF totaling $1.5mn, plans to complete three studies over the Q4 2014 to Q1 2015 timeframe: (1) the CTH-105 pilot study in patients with Parkinson's disease in Q4 2014; (2) the CTH-200 bioavailability study in Q4 2014 - Q1 2015; and (3) the CTH-300a efficacy study in apomorphine naïve patients in Q4 2014 - Q1 2015. The CTH-105 and CTH-300a studies are critical as they are the first studies of APL-130277 in Parkinson's patients. These studies should provide a steady stream of news flow and catalysts for Cynapsus shares over the upcoming quarters. In our November 2013 Cynapsus initiation report, we modeled in $270mn and $670mn in peak annual US and global sales, respectively. With a market cap of C$53.7mn, Cynapsus is trading at roughly 1/10th the purchase price of Civitas.
The note is available here: CTH Company Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will also be available on these platforms.
Please review important disclosures on our website at www.seethruequity.com.
About Cynapsus Therapeutics
Cynapsus is a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of OFF motor symptoms of Parkinson`s disease. Cynapsus` drug candidate, APL-130277, is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) to rescue patients from OFF episodes. Cynapsus is focused on maximizing the value of APL-130277 by completing pivotal studies in advance of a New Drug Application (NDA) expected to be submitted in 2016.
Over one million people in the U.S. and an estimated 4 to 6 million people globally suffer from Parkinson's disease. Parkinson`s disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. Based on a recent study and the results of the Corporation`s Global 500 Neurologists Survey, it is estimated that between 25 percent and 50 percent of patients experience OFF episodes in which they have impaired movement or speaking capabilities. Current medications only control the disease`s symptoms, and most drugs become less effective over time as the disease progresses.
More information about Cynapsus (CTH.V) (CYNAF) is available at www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon
SeeThruEquity
(646) 495-0939
SOURCE: SeeThruEquity
